Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KLU156 vs Coartem in Uncomplicated Plasmodium Falciparum Malaria
NCT05842954Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of ganaplacide + lumefantrine-SDF in Plasmodium falciparum malaria (4 arms), sponsored by Novartis. Primary endpoints: PCR-corrected Adequate Clinical and Parasitological Response at Day 29 and Uncorrected Adequate Clinical and Parasitological Response at Day 29. Started Mar 2024; status: completed.
02
Drugs
ganaplacide + lumefantrine-SDF
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT05842954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05842954.